TRP channels in prostate cancer: The good, the bad and the ugly?

Asian Journal of Andrology

Volumn 13, Issue 5, 2011, Pages 673-676

  Gkika, Dimitra ^a,b   Prevarskaya, Natalia ^a,b  

^a Université des Sciences et Technologies de Lille   (France)

^b UNIV LILLE   (France)

Author keywords

ion channel; lysophospholipids; migration; neuroendocrine; prostate cancer; PSA; transient receptor potential (TRP) channels; TRP channels; TRPM8; TRPV2; TRPV6

Indexed keywords

ION CHANNEL; PHOSPHOLIPID; PROSTATE SPECIFIC ANTIGEN; SMALL INTERFERING RNA; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL 2; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; TRANSIENT RECEPTOR POTENTIAL CHANNEL AFFECTING AGENT; UNCLASSIFIED DRUG; WS 12;

APOPTOSIS; CANCER CELL; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; DRUG TARGETING; HUMAN; NONHUMAN; PROSTATE CANCER; REVIEW;

APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; MALE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; TRPC CATION CHANNELS;

EID: 80052453345     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2011.18     Document Type: Review

References (34)

1. Montell C, Birnbaumer L, Flockerzi V, Bindels RJ, Bruford EA et al. A unified nomenclature for the superfamily of TRP cation channels. Mol Cell 2002; 9: 229-31.
2. Clapham DE. TRP channels as cellular sensors. Nature 2003; 426: 517-24.
3. Clapham DE, Runnels LW, Strubing C. The TRP ion channel family. Nat Rev Neurosci 2001; 2: 387-96.
4. Nilius B, Owsianik G, Voets T, Peters JA. Transient receptor potential cation channels in disease. Physiol Rev 2007; 87: 165-217.
5. Duncan LM, Deeds J, Hunter J, Shao J, Holmgren LM et al. Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res 1998; 58: 1515-20.
6. 21 entry and proliferation of prostate cancer epithelial cells. Cancer Res 2006; 66: 2038-47.
7. Tsavaler L, Shapero MH, Morkowski S, Laus R. Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res 2001; 61: 3760-9.
8. Wissenbach U, Niemeyer BA, Fixemer T, Schneidewind A, Trost C et al. Expression of CaT-like, a novel calcium-selective channel, correlates with the malignancy of prostate cancer. J Biol Chem 2001; 276: 19461-8.
9. Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI et al. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 2003; 63: 4196-203.
10. Bidaux G, Flourakis M, Thebault S, Zholos A, Beck B et al. Prostate cell differentiation status determines transient receptor potential melastatin member 8 channel subcellular localization and function. J Clin Invest 2007; 117: 1647-57.
11. Bidaux G, Roudbaraki M, Merle C, Crepin A, Delcourt P et al. Evidence for specific TRPM8 expression in human prostate secretory epithelial cells: functional androgen receptor requirement. Endocr Relat Cancer 2005; 12: 367-82.
12. Thebault S, Lemonnier L, Bidaux G, Flourakis M, Bavencoffe A et al. Novel role of cold/menthol-sensitive transient receptor potential melastatine family member 8 (TRPM8) in the activation of store-operated channels in LNCaP human prostate cancer epithelial cells. J Biol Chem 2005; 280: 39423-35.
13. 21 channel required for the survival of prostate cancer cells. Cancer Res 2004; 64: 8365-73.
14. Prevarskaya N, Zhang L, Barritt G. TRP channels in cancer. Biochim Biophys Acta 2007; 1772: 937-46.
15. 21 current in human prostate cancer LNCaP cells: involvement in apoptosis. J Physiol 2000; 527 (Pt 1): 71-83.
16. 21 homeostasis and store-operated channels in prostate cancer cells. Cancer Cell 2002; 1: 169-79.
17. 21 homeostasis and apoptotic resistance of neuroendocrine- differentiated prostate cancer cells. Cell Death Differ 2004; 11: 321-30.
18. Gkika D, Flourakis M, Lemonnier L, Prevarskaya N. PSA reduces prostate cancer cell motility by stimulating TRPM8 activity and plasma membrane expression. Oncogene 2010; 29: 4611-6.
19. Heidtmann HH, Nettelbeck DM, Mingels A, Jager R, Welker HG et al. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer 1999; 81: 1269-73.
20. Yang ZH, Wang XH, Wang HP, Hu LQ. Effects of TRPM8 on the proliferation and motility of prostate cancer PC-3 cells. Asian J Androl 2009; 11: 157-65.
21. 21-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression. Oncogene 2003; 22: 7858-61.
22. 21/NFAT-dependent pathways. Oncogene 2007; 26: 7380-5.
23. 1A-adrenoceptor in androgen-independent prostate cancer cells. PLoS One 2009; 4: e7068.
24. Monet M, Lehen'kyi V, Gackiere F, Firlej V, Vandenberghe M et al. Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance. Cancer Res 2010; 70: 1225-35.
25. Weinstein MH, Partin AW, Veltri RW, Epstein JI. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Human Pathol 1996; 27: 683-7.
26. Kanzaki M, Zhang YQ, Mashima H, Li L, Shibata H et al. Translocation of a calcium-permeable cation channel induced by insulin-like growth factor-I. Nat Cell Biol 1999; 1: 165-70.
27. Monet M, Gkika D, Lehen'kyi V, Pourtier A, Vanden Abeele F et al. Lysophospholipids stimulate prostate cancer cell migration via TRPV2 channel activation. Biochim Biophys Acta 2009; 1793: 528-39.
28. 1, p42 and p38alpha. Biochim Biophys Acta 2007; 1771: 883-92.
29. Raj GV, Sekula JA, Guo R, Madden JF, Daaka Y. Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-kappaB. Prostate 2004; 61: 105-13.
30. Daaka Y. Mitogenic action of LPA in prostate. Biochim Biophys Acta 2002; 1582: 265-9.
31. Zhang L, Barritt GJ. TRPM8 in prostate cancer cells: a potential diagnostic and prognostic marker with a secretory function? Endocr Relat Cancer 2006; 13: 27-38.
32. Andersen OS. Perspectives on how to drug an ion channel. J Gen Physiol 2008; 131: 395-7.
33. Arcangeli A, Crociani O, Lastraioli E, Masi A, Pillozzi S et al. Targeting ion channels in cancer: a novel frontier in antineoplastic therapy. Curr Med Chem 2009; 16: 66-93.
34. Beck B, Bidaux G, Bavencoffe A, Lemonnier L, Thebault S et al. Prospects for prostate cancer imaging and therapy using high-affinity TRPM8 activators. Cell Calcium 2007; 41: 285-94.